Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease
- PMID: 35860792
- PMCID: PMC9286327
- DOI: 10.1002/dad2.12325
Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease
Abstract
Introduction: The aim of this study was to develop a conditional normative model for Rey's Auditory Verbal Learning Test (AVLT) that accounts for practice effects.
Methods: In our normative sample, robust conditional norms were derived from 1001 cognitively unimpaired (CU) adults ages 50 to 89 who completed the AVLT up to eight times. Linear mixed-effects models adjusted for baseline performance, prior test exposures, time, demographics, and interaction terms. In our preliminary validation, mean performance on conditional and typical normative scores across two to four completed follow-up tests in preclinical Alzheimer's disease participants at baseline with positive amyloid and tau positron emission (n = 27 CU amyloid [A]+tau[T]+) was compared to biomarker negative individuals (n = 269 CU A-T-).
Results: AVLT performance using typical norms did not differ across A+T+ and A-T- groups. Conditional norms z-scores were lower in the A+T+ relative to the A-T- group for 30-minute recall (P = .033) and sum of trials (P = .030).
Discussion: Conditional normative methods that account for practice effects show promise for identifying longitudinal cognitive decline.
Keywords: Alzheimer's disease; Rey Auditory Verbal Learning Test; amyloid; biomarker; memory; mild cognitive impairment; neuropsychology; practice effects; reliable change index (RCI); robust normative data; standardized regression‐based change scores (SRB); tau; transitional cognitive decline; validity.
© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
Conflict of interest statement
NHS & MMMi have served as consultants to Biogen and Lundbeck. D.S.K. serves on a Data Safety Monitoring Board for the DIAN‐TU study and is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the University of Southern California. R.C.P. has served as a consultant for Hoffman‐La Roche Inc., Merk Inc., Genentech Inc., Biogen Inc., Eisai, Inc., and GE Healthcare. WKK has received research funding from Biogen, Roche, and AstraZeneca. The authors report no conflicts of interest. All other authors declare no conflicts of interest.
Figures
References
-
- Heilbronner RL, Sweet JJ, Attix DK, Krull KR, Henry GK, Hart RP. Official position of the American Academy of Clinical Neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. Clin Neuropsychol. 2010;24(8):1267‐1278. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources